Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic response to a novel enzyme-targeting radiosensitization treatment (Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas) in patients with recurrent breast cancer.
Aoyama N, Ogawa Y, Yasuoka M, Takahashi M, Iwasa H, Miyatake K, Yamanishi T, Hamada N, Tamura T, Nishioka A, Yamagami T. Aoyama N, et al. Among authors: iwasa h. Oncol Lett. 2016 Jul;12(1):29-34. doi: 10.3892/ol.2016.4589. Epub 2016 May 16. Oncol Lett. 2016. PMID: 27347095 Free PMC article.
Therapeutic response to a novel enzyme-targeting radiosensitization treatment (KORTUC II) for residual lesions in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin and cyclophosphamide or taxane.
Aoyama N, Ogawa Y, Yasuoka M, Iwasa H, Miyatake K, Yoshimatsu R, Yamanishi T, Hamada N, Tamura T, Kobayashi K, Murata Y, Yamagami T, Miyamura M. Aoyama N, et al. Among authors: iwasa h. Oncol Lett. 2017 Jan;13(1):69-76. doi: 10.3892/ol.2016.5456. Epub 2016 Dec 1. Oncol Lett. 2017. PMID: 28123524 Free PMC article.
Therapeutic results of a novel enzyme-targeting radiosensitization treatment, Kochi oxydol-radiation therapy for unresectable carcinomas II, in patients with stage I primary breast cancer.
Aoyama N, Ogawa Y, Yasuoka M, Ohgi K, Iwasa H, Miyatake K, Yoshimatsu R, Yamanishi T, Hamada N, Tamura T, Kobayashi K, Murata Y, Miyamura M, Yamagami T. Aoyama N, et al. Among authors: iwasa h. Oncol Lett. 2017 Jun;13(6):4741-4747. doi: 10.3892/ol.2017.6074. Epub 2017 Apr 21. Oncol Lett. 2017. PMID: 28599475 Free PMC article.
Pancreatic FDG uptake on follow-up PET/CT in patients with cancer.
Iwasa H, Murata Y, Nishimori M, Miyatake K, Kohsaki S, Hayashi N, Akagi N, Kohsaki T, Uchida K, Yamagami T. Iwasa H, et al. Oncol Lett. 2021 Apr;21(4):270. doi: 10.3892/ol.2021.12531. Epub 2021 Feb 9. Oncol Lett. 2021. PMID: 33717267 Free PMC article.
Predicting the pathological invasiveness of early lung adenocarcinoma prior to surgery using Deauville criteria: reliability and validity.
Nishimori M, Iwasa H, Nakaji K, Nitta N, Miyatake K, Yoshimatsu R, Yamanishi T, Matsumoto T, Kato M, Hayashi N, Toi M, Tamura M, Yamagami T. Nishimori M, et al. Among authors: iwasa h. Jpn J Radiol. 2023 Jul;41(7):768-776. doi: 10.1007/s11604-023-01397-z. Epub 2023 Feb 8. Jpn J Radiol. 2023. PMID: 36752955 Free PMC article.
285 results